Results 81 to 90 of about 178 (122)

Myogenesis gone awry: the role of developmental pathways in rhabdomyosarcoma

Frontiers in Cell and Developmental Biology
Rhabdomyosarcoma is a soft-tissue sarcoma that occurs most frequently in pediatric patients and has poor survival rates in patients with recurrent or metastatic disease.
Annika L. Gustafson, Annika L. Gustafson, Annika L. Gustafson, Adam D. Durbin, Kristin B. Artinger, Heide L. Ford, Heide L. Ford, Heide L. Ford   +7 more
doaj   +1 more source

TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma

Experimental Hematology & Oncology
Rhabdomyosarcoma (RMS), such as other childhood tumors, has witnessed treatment advancements in recent years. However, high-risk patients continue to face poor survival rates, often attributed to the presence of the PAX3/7-FOXO1 fusion proteins, which ...
Gabriel Gallo-Oller, Guillem Pons, Júlia Sansa-Girona, Natalia Navarro, Patricia Zarzosa, Lia García-Gilabert, Paula Cabré-Fernandez, Gabriela Guillén Burrieza, Lorena Valero-Arrese, Miguel F. Segura, José M. Lizcano, José Sánchez de Toledo, Lucas Moreno, Soledad Gallego, Josep Roma   +14 more
doaj   +1 more source

Transcriptional regulation of genes by MYCN in PAX3::FOXO1-positive rhabdomyosarcomas and their roles in cell cycle progression

EJC Paediatric Oncology
Background: MYCN amplification and high expression is associated with pediatric malignancies including neuroblastoma and alveolar rhabdomyosarcoma. MYCN transcription in alveolar rhabdomyosarcomas is driven by a feedback loop with the PAX3::FOXO1 fusion ...
Zoë S. Walters, Daniel Leongamornlert, Barbara Villarejo-Balcells, Carmen Tse, Reuben Pengelly, Ian Titley, Janet Shipley   +6 more
doaj   +1 more source

Generation of an iPSC-derived alveolar rhabdomyosarcoma cell line during directed endothelial differentiation

Stem Cell Research
Alveolar rhabdomyosarcoma (ARMS) is an aggressive soft tissue sarcoma typically driven by the oncofusion protein PAX3::FOXO1 (P3F). Despite ARMS tumor histology and transcriptome resembling skeletal muscle, these tumors arise in areas devoid of skeletal ...
Randolph K. Larsen, IV, Madeline B. Searcy, Bradley T. Stevens, Katherine E. Gadek, Yang Zhang, Brian J. Abraham, Mark E. Hatley   +6 more
doaj   +1 more source

PAX3/FOXO1 Fusion Protein [PDF]

, 2020
openaire   +1 more source

PAX3/FOXO1 Fusion Gene [PDF]

, 2020
openaire   +1 more source

A rare adult case of primary uterine rhabdomyosarcoma with mixed pattern: a clinicopathological & immunohistochemical study with literature review

Diagnostic Pathology
Background Rhabdomyosarcomas are aggressive tumors that comprise a group of morphologically similar but biologically diverse lesions. Owing to its rarity, Mixed pattern RMS (ARMS and ERMS) constitutes a diagnostic and therapeutic dilemma.
Nehal K.H. Kamel, Eiman Adel Hasby
doaj   +1 more source

PAX3-FOXO1: Zooming in on an “undruggable” target

Seminars in Cancer Biology, 2018
Driver oncogenes are prime targets for therapy in tumors many of which, including leukemias and sarcomas, express recurrent fusion transcription factors. One specific example for such a cancer type is alveolar rhabdomyosarcoma, which is associated in the majority of cases with the fusion protein PAX3-FOXO1.
Beat Schafer, Marco Wachtel
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Targeting KDM4 for treating PAX3-FOXO1–driven alveolar rhabdomyosarcoma

Science Translational Medicine, 2022
Chimeric transcription factors drive lineage-specific oncogenesis but are notoriously difficult to target. Alveolar rhabdomyosarcoma (RMS) is an aggressive childhood soft tissue sarcoma transformed by the pathognomonic Paired Box 3–Forkhead Box O1 (PAX3-FOXO1) fusion protein, which governs a core regulatory circuitry transcription factor ...
Qiong Wu, Taosheng Chen, Haiyan Tan
exaly   +3 more sources

Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma [PDF]

Journal of Clinical Investigation, 2016
A vast number of cancer genes are transcription factors that drive tumorigenesis as oncogenic fusion proteins. Although the direct targeting of transcription factors remains challenging, therapies aimed at oncogenic fusion proteins are attractive as potential treatments for cancer.
Beat Schafer, Paolo Nanni, Raffaella Santoro   +2 more
exaly   +4 more sources